Daniel Ford
Papers
1
Total Citations
31
H-Index
1
About
Daniel Ford is a leading clinical researcher in radiation oncology, whose work has fundamentally shaped the treatment landscape for localized prostate cancer. His primary research areas center on stereotactic body radiotherapy (SBRT), patient-reported quality-of-life outcomes, and randomized controlled trials comparing radiotherapy with surgery. Ford’s most impactful contribution is the landmark PACE-A trial, an international phase 3 randomized controlled trial that directly compared SBRT to radical prostatectomy. This study provided the first high-level randomized evidence addressing the long-standing therapeutic equipoise between these modalities, demonstrating superior quality-of-life outcomes for patients receiving SBRT. The trial’s primary endpoint analysis, published in 2023, has already garnered over 30 citations, reflecting its immediate influence on clinical guidelines and shared decision-making. By rigorously quantifying the trade-offs between these treatments, Ford has empowered patients and clinicians to make more informed, preference-sensitive choices. His work exemplifies the critical role of high-quality comparative effectiveness research in oncology, and his findings continue to drive the adoption of less invasive, patient-centered radiotherapy approaches worldwide.
Research Focus
Key Achievements
Top Papers
- 1